EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Industry Insights: Regulatory progress and AI-driven advances in nucleic acid therapeutics

Jokubas Leikauskas

Nucleic Acid Insights · 13.05.2026 · 3 (3) · 199–203

DOI: 10.18609/nai.2026.026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acid Insights, online erschienen am 13.05.2026. Verfasst von Jokubas Leikauskas. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Across March and April 2026, activity in the nucleic acid therapeutics field reflected broad regulatory momentum and continued clinical advancement across multiple RNA modalities. Regulatory highlights included US FDA Priority Review designations for Ionis' antisense oligonucleotide (ASO) zilganersen in Alexander disease, alongside EMA acceptance of GSK's marketing authorisation application for the ASO bepirovirsen in chronic hepatitis B. Clinical milestones featured first-in-human trials of novel modalities, including Alltrna's transfer RNA therapeutic AP003 and AIRNA's RNA-editing candidate AIR-001. AI-driven discovery also advanced, with Asimov launching an integrated RNA optimisation platform and ProQR partnering with Ginkgo Bioworks to scale high-throughput data generation for its RNA editing pipeline.

Zitieren

APA

Leikauskas, J. (2026). Industry Insights: Regulatory progress and AI-driven advances in nucleic acid therapeutics. Nucleic Acid Insights, 3(3), 199–203. https://doi.org/10.18609/nai.2026.026

Vancouver

Leikauskas J. Industry Insights: Regulatory progress and AI-driven advances in nucleic acid therapeutics. Nucleic Acid Insights. 2026;3(3):199–203. doi:10.18609/nai.2026.026

BibTeX
@article{Leikauskas2026,
  author = {Leikauskas, Jokubas},
  title = {Industry Insights: Regulatory progress and AI-driven advances in nucleic acid therapeutics},
  journal = {Nucleic Acid Insights},
  year = {2026},
  volume = {3},
  number = {3},
  pages = {199–203},
  doi = {10.18609/nai.2026.026}
}
Kostenlos starten →